Emerging retatrutide, a twin -action treatment targeting equally GLP-1 and GIP receptors, is generating considerable interest within the healthcare community. Initial clinical trials have demonstrated significant reductions in overall size and gains in metabolic markers for patients with overweight. Experts believe this novel approach has the po… Read More